The RECOVERY, ACTIV-4a and REMAP-CAP trials evaluated the effects of aspirin or P2Y12 ADP-receptor antagonists in hospitalised patients admitted with mild to severe COVID-19 [26, 33, 34]. Here, P2RY12 is linked to COVID-19.